HIV Infection
647
23
34
493
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
126 trials with published results (19%)
Research Maturity
493 completed trials (76% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.5%
42 terminated out of 647 trials
92.1%
+5.6% vs benchmark
26%
165 trials in Phase 3/4
26%
126 of 493 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 493 completed trials
Clinical Trials (647)
Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma
MAPS PrEP Van Study
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey
Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women
HIV Disclosure and Medication Adherence, a Pilot Study
Baricitinib Curative Repression of HIV-1
Colchicine to Reduce Coronary Artery Inflammation in People With HIV
An Open-label Randomized Trial Evaluating the Acceptability, Quality of Care, Patient Satisfaction, and Cost-effectiveness of Monitoring Provided by Nurses or Physicians for People Using HIV Pre-exposure Prophylaxis
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Pilot Study to Evaluate Efficacy and Safety of Switching to BIC/FTC/TAF in PWH With a Previous Virological Failure Under CAB/RPV LAI
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial
#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
Dental Management of Patients With HIV in Pays de la Loire
MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer